University of Cambridge
The METL3 enzyme deposits a mehtyl group at the N6 position of adenosine in mRNA
Case Studies

Storm Therapeutics: targeting cancer

19 January 2021
News

Annual awards recognise Cambridge innovation and excellence

23 March 2018
News

Cambridge spin-out STORM Therapeutics expands collaboration with Evotec

27 July 2017
News

Storm Therapeutics announces appointment of CEO and Chairman

24 February 2017
News

Storm Therapeutics secures £12m investment

28 June 2016